Evidence map›Paper›PMID 37245084›Full record

ReviewAnnals of neurology2023

When Alzheimer's is LATE: Why Does it Matter?

Peter T Nelson, Julie A Schneider, Gregory A Jicha, Michael Tran Duong, David A Wolk

Open access · bronzeAbstract readReview
In one paragraph

Review in Annals of neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 1 pooled it
9.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.

  1. Clinical criteria for limbic-predominant age-related TDP-43 encephalopathy.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Brain morphometry patterns in the presence of Alzheimer's disease and/or LATE neuropathologic changes.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Brain magnetic resonance imaging biomarkers for future frailty; sub-study of FINGER trial.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Observational
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Clinical and molecular correlates of limbic age-related TDP-43 encephalopathy (LATE)European journal of nuclear medicine and molecular imaging · 2025
    Article
  19. Development of [Nature communications · 2025
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Peter T NelsonDepartment of Pathology and Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY.ORCID 0000-0002-6161-1265
Julie A SchneiderDepartments of Pathology and Neurological Science, Rush University Medical College, Chicago, IL.
Gregory A JichaDepartment of Neurology and Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY.
Michael Tran DuongDepartment of Neurology, University of Pennsylvania, Philadelphia, PA.
David A WolkDepartment of Neurology, University of Pennsylvania, Philadelphia, PA.
University of Kentucky · USUniversity of Pennsylvania · USRush University Medical Center · US

Funding

Research Education ComponentP30AG072979 · NIA · UNIVERSITY OF PENNSYLVANIA · PI DAVID A WOLK · 2021 to 2026
$24.8M
Rush Alzheimer's Disease Research CenterP30AG072975 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI Lisa L Barnes, Julie A. Schneider · 2021 to 2026
$24.7M
University of Kentucky Alzheimer's Disease Research CenterP30AG072946 · NIA · UNIVERSITY OF KENTUCKY · PI BRIAN Timothy GOLD · 2021 to 2026
$23.5M
Characterizing TDP-43 related hippocampal degeneration and memory loss in agingR01AG067482 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI SCHNEIDER, JULIE A. · 2020 to 2024
$6.8M
Characterization of relationship between tau pathology and neurodegeneration in Alzheimer's disease using multimodal imagingR01AG072796 · NIA · UNIVERSITY OF PENNSYLVANIA · PI Sandhitsu Das, DAVID A WOLK · 2022 to 2026
$4.0M
Safety and modulation of ABCC9 pathways by nicorandil for the treatment of hippocampal sclerosis of aging (SMArT–HS)R01AG061111 · NIA · UNIVERSITY OF KENTUCKY · PI JICHA, GREGORY A, NELSON, PETER T. · 2019 to 2025
$3.6M
Longitudinal validation of cerebral small vessel disease biomarkers in diverse community-based older adults without dementiaU01NS100599 · NINDS · RUSH UNIVERSITY MEDICAL CENTER · PI ARFANAKIS, KONSTANTINOS, SCHNEIDER, JULIE A. · 2023 to 2025
$3.5M
Modulators of Medial Temporal Lobe Subregion Structure and Function in Normal and Pathological AgingR01AG055005 · NIA · UNIVERSITY OF PENNSYLVANIA · PI WOLK, DAVID A · 2017 to 2021
$3.3M
In-vivo MRI-based prediction of TDP43 pathology in agingR01AG064233 · NIA · ILLINOIS INSTITUTE OF TECHNOLOGY · PI ARFANAKIS, KONSTANTINOS, SCHNEIDER, JULIE A. · 2019 to 2023
$3.3M
Age-related TDP-43 neuropathology: using disease-driving mechanisms to guide classificationRF1NS118584 · NINDS · METHODIST HOSPITAL RESEARCH INSTITUTE · PI CYKOWSKI, MATTHEW DANIEL, NELSON, PETER T. · 2020 to 2020
$3.2M
Longitudinal validation of cerebral small vessel disease biomarkers in diverse community-based older adults without dementiaUF1NS100599 · NINDS · RUSH UNIVERSITY MEDICAL CENTER · PI ARFANAKIS, KONSTANTINOS, SCHNEIDER, JULIE A. · 2021 to 2021
$2.5M
Epidemiologic Study of TDP-43 Pathology in Aging and DementiaR01AG042210 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI SCHNEIDER, JULIE A. · 2012 to 2018
$2.4M
NIA NIH HHS F30 AG074524NIA NIH HHS P30 AG072946NIA NIH HHS P30 AG072975NIA NIH HHS P30 AG072979NIA NIH HHS R01 AG042210NIA NIH HHS R01 AG055005NIA NIH HHS R01 AG061111NIA NIH HHS R01 AG064233NIA NIH HHS R01 AG067482NIA NIH HHS R01 AG072796NIA NIH HHS RF1 AG069474NIA NIH HHS RF1 AG082339NINDS NIH HHS RF1 NS118584NINDS NIH HHS U01 NS100599NINDS NIH HHS UF1 NS100599
6 · The paper itself

Abstract

Recent therapeutic advances provide heightened motivation for accurate diagnosis of the underlying biologic causes of dementia. This review focuses on the importance of clinical recognition of limbic-predominant age-related TDP-43 encephalopathy (LATE). LATE affects approximately one-quarter of older adults and produces an amnestic syndrome that is commonly mistaken for Alzheimer's disease (AD). Although AD and LATE often co-occur in the same patients, these diseases differ in the protein aggregates driving neuropathology (Aβ amyloid/tau vs TDP-43). This review discusses signs and symptoms, relevant diagnostic testing, and potential treatment implications for LATE that may be helpful for physicians, patients, and families. ANN NEUROL 2023;94:211-222.

Indexed as

Alzheimer DiseaseAgedAmyloid beta-PeptidesDementiaHumanstau ProteinsTDP-43 ProteinopathiesAmyloid beta-Peptidestau Proteins

Identifiers

PMID37245084
PMCPMC10516307
OpenAlexW4378569287

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.